MDXXF (Pharmala Biotech Holdings) Additional Paid-In Capital : $0.71 Mil(As of Feb. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Additional Paid-In Capital?

Pharmala Biotech Holdings's quarterly additional paid-in capital declined from Aug. 2024 ($0.63 Mil) to Nov. 2024 ($0.61 Mil) but then increased from Nov. 2024 ($0.61 Mil) to Feb. 2025 ($0.71 Mil).

Pharmala Biotech Holdings's annual additional paid-in capital declined from Aug. 2022 ($0.29 Mil) to Aug. 2023 ($0.28 Mil) but then increased from Aug. 2023 ($0.28 Mil) to Aug. 2024 ($0.63 Mil).

Pharmala Biotech Holdings Additional Paid-In Capital Historical Data

The historical data trend for Pharmala Biotech Holdings's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Additional Paid-In Capital Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Additional Paid-In Capital

0.11

0.29

0.28

0.63

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24	Feb25
Additional Paid-In Capital	Get a 7-Day Free Trial										0.25	0.30	0.63	0.61	0.71

Pharmala Biotech Holdings Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Pharmala Biotech Holdings Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

MDMA:Canada

Address

1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.